More Articles

Access and Evidence

Keeping it real: How data is driving healthcare reform in China 

Pamela Whitby, (Jun 8, 2021)

China’s healthcare market is ripe for those capable of helping it capture the vast potential of real-world data

On the journey from pill to platform

Andrew Stone, (Jun 3, 2021)

For AstraZeneca’s Alex Bedenkov, investing more in post-pandemic medical capabilities is just the start of a far more profound organisation-wide transformation
Patients and Medical

Optimizing patient Engagement in Trials

Joseph Constance, (May 23, 2021)

The importance of involving the patient at all stages of trials post-pandemic has never been clearer
Patients and Medical

Fixing the broken patient search experience

Andrew Stone, (May 23, 2021)

There’s opportunity as well as danger in the billion healthcare searches made every day. Why isn’t pharma tuning in?
Access and Evidence

Including the caregiver in access submissions

Katie Osborne, (May 23, 2021)

Partnering with caregivers can help build a more powerful case for re-imbursement if pharma can gather the right evidence

From insight to action in medical affairs

Nicola Davies, (May 6, 2021)

Physicians’ increasingly digital-first consumption of disease state education offers pharma a way to understand their needs more deeply and so find better ways to serve them

How collaboration will strengthen the future of cell and gene therapies

Adlai Goldberg, (Apr 6, 2021)

As clinical science continues to deliver on the promise of CGT, how can the industry make them available and affordable at scale?

How US pharma is charting a new course in a changed world

Tom Disley, (Apr 6, 2021)

Post-Trump and post pandemic, pharma in the US is eyeing emerging commercial and clinical opportunities, but must reckon with potential storms ahead

Redefining the role of the MSL in a changed world

Andrew Stone, (Mar 24, 2021)

MSLs will need to respond to the growing demands being placed on them in the new normal by adopting new approaches, capabilities and skill sets

Accelerating commercial success in CAGT

Dean Griffiths, (Mar 22, 2021)

To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in